

Fibroblast growth factor 23 and inflammation in chronic kidney disease

Jair Munoz Mendoza¹, Tamara Isakova¹, Ana C. Ricardo², Huiliang Xie³, Sankar Navaneethan⁴, Amanda H. Anderson⁵, Lydia A. Bazzano⁶, Dawei Xie⁵, Matthias Kretzler⁷, Lisa Nessel⁵, L. Lee Hamm⁸, Lavinia Negrea⁹, Mary B. Leonard^{5,10}, Dominic Raj¹¹, and Myles Wolf¹ for the Chronic Renal Insufficiency Cohort

From

¹ Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA

²Section of Nephrology, Department of Medicine, University of Illinois, Chicago, Illinois, USA

³Department of Epidemiology and Public Health, University of Miami, University of Miami, Miller School of Medicine, Miami, FL, USA.

⁴Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland, OH, USA

⁵Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

⁶Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.

⁷Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA

⁸Hypertension and Renal Center of Excellence, Departments of Medicine, Physiology, and Epidemiology, Tulane University Schools of Medicine and Public Health and Tropical Medicine, New Orleans, LA. USA

⁹Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA

¹⁰Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

¹¹Division of Nephrology and Hypertension, Department of Medicine, George Washington University, Washington DC, USA